MedPharm Announces Formation of US Subsidiary & First Appointment


MedPharm recently announced the formation of its new US-based laboratories, MP Pharma Services Inc. With a targeted operational date in Q1 2016, the services offered in the US will initially focus on topical and transdermal formulation performance testing. Among other services, the facility will provide access to MedPharm’s unique, validated in vitro models, complementing the UK based operation and offering a significant increase in capacity, as well as new services to the company’s clients. It is an important expansion for MedPharm with US-based business accounting for 50% of company revenues. The operation will be led by Jon Lenn who has been recruited as the first of a number of new appointments to join the new facility in RTP, North Carolina.

“MedPharm is already the leading company in this field, and we continue to cement this reputation by adding new services and bringing in the latest know-how to the company. The expertise that Jon brings to the table is of incredible value as we expand the company into the US. As well as offering an increase in services and capacity to all of our partners, our clients in North and South America will now also benefit from having the opportunity for even closer contact with MedPharm,”said Dr. Andrew Muddle, CEO.

Jon brings with him an extensive and impressive portfolio of experience in topical and transdermal drug delivery. Jon has held senior positions in Stiefel and GSK, specializing in skin biology and topical and transdermal formulation development. During his career, he has been instrumental in numerous successful NDA and ANDA regulatory submissions including EVOCLIN, VERDESO, OLUX-E, EXTINA, VELTIN, SORILUX, FABIOR, & DUAC LD.

“We are all delighted to be able to bring Jon on board. He brings with him a vast wealth of experience from his time in industry, and we are certain that our clients will benefit enormously from his input in their projects at MedPharm,” added Prof. Brown, CSO states.

MedPharm is the leading topical and transdermal pharmaceutical development company. It is recognized internationally for its expertise in transdermal and topical (skin, nail, nose, lungs, and other mucosal membranes) formulations and drug delivery systems. Established in 1999, MedPharm has built a worldwide reputation for its unique and highly specialized service in contract research, development and manufacturing. The company offers a complete suite of development options from simple feasibility tests, formulation and dosage form design, optimization and testing through to preparation of GMP clinical supplies for Phase I/II. The company operates a hybrid business model, with a CRO business and a development program with a substantial patent portfolio of novel topical and transdermal drug delivery systems, including MedSpray, MedRo, and AquaRMed. It has produced these innovations by exploiting its internal product development expertise. MedPharm’s laboratories in the UK are routinely inspected by Regulatory Authorities and are certified for GMP and GLP studies. For more information, visit www.medpharm.co.uk.